• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Comparison of improved prognosis between hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma
【24h】

Comparison of improved prognosis between hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma

机译：比较肝炎之间的改善预后B和C型肝炎应承担相关的肝细胞癌

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim Treatment strategies for hepatocellular carcinoma (HCC) have been advanced. The aim of this study was to compare the change of the prognosis between hepatitis B‐related HCC (B‐HCC) and hepatitis C‐related HCC (C‐HCC) in the last two decades. Methods We enrolled 166 B‐HCC patients who underwent percutaneous ablation between 1990 and 2009. Patients were divided into three groups according to the treatment time period: 1990–1995 (cohort 1, n ?=?19), 1996–2002 (cohort 2, n ?=?49) and 2003–2009 (cohort 3, n ?=?98). We enrolled 1219 C‐HCC patients who underwent percutaneous ablation during the same period ( n ?=?190, 413 and 616, respectively.). Interferon and nucleoside/nucleotide analog use was investigated. Prognosis was evaluated for each cohort using the Kaplan–Meier method and a multivariate Cox proportional hazard regression model. Results Two (11%), 24 (49%) and 80 (82%) B‐HCC patients received nucleoside/nucleotide analogs during the follow‐up period in cohorts 1–3, respectively. Among them 1, 18 and 62 patients achieved viral remission, respectively. Thirty‐four (18%), 35 (8%) and 84 (14%) C‐HCC patients received interferon therapy, respectively. The 5‐year B‐HCC ( P ??0.001) survival rates were 52.6%, 61.1% and 81.6% for cohorts 1–3, respectively. However, the survival rates were 55.6%, 58.8% and 61.1% for C‐HCC ( P ?=?0.12), respectively. The B‐HCC prognosis improved dramatically ( P ??0.001) over time, whereas the prognosis of C‐HCC improved moderately ( P ?=?0.01). Conclusion The prognosis of B‐HCC has improved dramatically over time, whereas that of C‐HCC has improved moderately.
机译：目的对肝细胞治疗策略癌(HCC)是先进的。本研究旨在比较的变化乙型肝炎相关肝癌应承担之间预后(B所致HCC)和丙型肝炎相关肝细胞癌(HCC)应承担的最后一个二十年。病人经皮消融在1990年和2009年之间。三组治疗时间期:1990 - 1995(组1,n = ? 19), 1996 - 2002(队列2 n = ? 49)和2003 - 2009(组3,n98年= ?)。在相同的接受经皮消融期(n = ?干扰素和核苷/核苷酸模拟使用被调查。每个队列使用kaplan meier和方法多变量Cox比例风险回归模型。B检测肝细胞癌患者接受核苷/核苷酸类似物群下了应承担的时期分别为1 - 3。分别病人实现病毒缓解。30量四个(18%),35(8%)和84 (14%)C肝细胞癌患者接受干扰素治疗,分别。存活率分别为52.6%、61.1%和81.6%分别组1 - 3。率分别为55.6%、58.8%和61.1% C检测肝细胞癌(P分别? = 0.12)。显著提高(P & ? 0.001)随着时间的推移,而C检测肝细胞癌的预后改善适度(P ? = 0.01)。B的检测肝癌已显著改善随着时间的推移,而C HCC适度改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号